research In situ detection of retinoid-X receptor expression in normal and psoriatic human skin
RXR-alpha is strongly expressed in both normal and psoriatic skin and may help in skin cell differentiation and hair growth.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch P146 A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata
Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.
research Successful treatment of frontal fibrosing alopecia with alitretinoin
Alitretinoin can effectively treat frontal fibrosing alopecia.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Scarring Alopecias in a Pediatric Trichology Clinic at a Tertiary Care Center
Low-dose isotretinoin is effective for treating pediatric scarring alopecia.
research Biopharmaceutical properties of adapalene loaded biocompatible microemulsions
Microemulsions improve adapalene's skin absorption for better acne treatment.
research Suppression of Vitamin D Receptor and Induction of Retinoid X Receptor α Expression During Squamous Differentiation of Cultured Keratinocytes
As skin cells mature, vitamin D receptor levels decrease while retinoid X receptor α levels increase.
research "Preparation and Physicochemical Characterization of Topical Niosomal Formulation of Minoxidil and Tretinoin"
A new hair loss treatment was created using minoxidil and tretinoin in stable niosomes, which effectively released the drugs over time.
research Retinoic acids shift skin stem cell fate
Retinoic acids temporarily change skin stem cells to a slower cycle and more differentiated state.
research Ethinylestradiol/salicylic acid/swertia japonica/tocopherol acetate
Two women had skin reactions from a hair loss treatment and got better after stopping use.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Successful Treatment of Alopecia Areata with Topical Calcipotriol
A boy with alopecia regrew hair using a vitamin D cream after other treatments failed.
research Molecular cloning of two novel types of peptidylarginine deiminase cDNAs from retinoic acid‐treated culture of a newborn rat keratinocyte cell line
Two new enzymes, PAD-R11 and PAD-R4, were cloned and showed activity, with PAD-R11 resembling epidermal enzymes.
research Topical Administration of 15‐Deoxy‐Δ12,14‐Prostaglandin J2 Using a Nonionic Cream: Effect on UVB‐Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in Mice
15d‐PGJ2 cream protects against UVB-induced skin damage in mice.
research P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
Ritlecitinib shows promise in improving severe alopecia areata, with 27% of patients seeing success.
research Efficacy and safety of oral alitretinoin in chronic hand eczema and palmoplantar pustulosis
Oral alitretinoin is effective for certain types of chronic hand eczema, with mild side effects.
research Oral isotretinoin for acne
Oral isotretinoin may slightly improve acne but increases the risk of side effects like dry lips and skin; more research is needed to understand its full risks and benefits.
research Vitamins
Taking too much vitamin A can cause health problems like bone pain and hair loss.
research Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.
research Rothmund Thomson syndrome with late onset and good preventive control of non-melanoma cancer with acitretin: case report
Acitretin effectively prevented skin cancer in a patient with late-onset Rothmund-Thomson syndrome.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
research Clinical Snippets
A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research P165 Real-world experience of ritlecitinib for the treatment of alopecia areata from an alopecia clinic in a large tertiary dermatology centre
Ritlecitinib is effective and safe for treating alopecia areata, especially in newer cases.
research Recommended treatment options in acne management
Use topical retinoids for most acne cases, sometimes combined with other treatments.
research RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia.
RUM-loaded SLN shows promise for treating acne and hair loss topically.
research THE ROLE OF ORAL SUPPLEMENTS IN MITIGATING COMMON ISOTRETINOIN SIDE EFFECTS: A COMPREHENSIVE REVIEW
Oral supplements like Vitamin E and Omega-3 can help reduce isotretinoin side effects.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.